Neovascularization Clinical Trial
Official title:
Pilot Study of Intravitreal Injection of Ranibizumab for Macular Telangiectasia With Neovascularization (MACTEL 1)
This study will examine whether the drug ranibizumab (Lucentis) can help prevent vision loss
in people with macular telangiectasia, a condition in which new blood vessels grow in the
retina at the back of the eye and can leak. Such changes in blood vessels are seen in other
diseases associated with changes in a body chemical called vascular endothelial growth factor
(VEGF). Ranibizumab is an anti-VEGF drug that is effective in treating another eye disease,
age-related macular degeneration, with similar changes in eye blood vessels.
People 18 years of age and older with macular telangiectasia in both eyes and new blood
vessel growth in at least one eye may be eligible for this study. They must have vision
better than 20/400 in the study eye.
Participants undergo the following procedures:
- Ranibizumab injections in the study eye at least four times over 12 weeks. Depending on
the response to treatment and the side effects, additional injections may be given every
4 weeks for up to 1 year. The eye is numbed before the injection and the eye area is
cleaned with an antiseptic. Antibiotic drops are used for 3 days following the injection
to prevent infection.
- Evaluations before starting treatment, at the time of each injection, and 8 weeks after
the last treatment:
- History and physical examination.
- Eye examination with dilation, microperimetry and photography: The eye examination
measures visual acuity, eye pressure and eye movements. For the microperimetry
test, subjects sit in front of a computer screen and press a button when they see a
light on the screen. Measurements and photographs of the retina are also taken.
- Fluorescein and indocyanine green angiography to examine the blood vessels in the
eye: A dye called fluorescein or indocyanine green is injected into a vein in the
arm. The dye travels through the veins to the blood vessels in the eyes. A camera
takes pictures of the dye as it flows through the blood vessels.
- Pregnancy test: Women who are able to become pregnant have a urine pregnancy test
before each ranibizumab injection.
Retinal telangiectasis is a group of rare, idiopathic retinal vascular anomalies affecting
the retinal capillaries in which irregular capillary dilation and incompetence occur in the
macula. This is group 2 in the Gass classification of idiopathic juxtafoveal telangiectasia
in which fluorescein angiography showed leakage with capillary dilation. These patients
typically are diagnosed in their fifth or sixth decade of life. Both sexes may be affected.
Minimal exudation, superficial retinal crystalline deposits, and right-angle venules
characterize this disorder. As the disease progresses, intraretinal pigment plaques and
intraretinal and eventually subretinal/choroidal neovascularization develop. The pathogenesis
of the disease is unknown. Because of the leakage of the retinal vessels and also the finding
of neovascularization, it is possible that vascular endothelial growth factor (VEGF) may be
implicated in this disease.
The purpose of this study is to evaluate the possible role of ranibizumab for the treatment
of eight participants with macular telangiectasia with hyperfluorescence on fluorescein
angiography, with vision better than 20/400, with neovascularization. The primary outcome of
this study will be the proportion of participants that lose 15 letters or more in ETDRS BCVA
at 12 months compared with baseline. The secondary outcomes measured at one year will include
the proportion of participants who lose 10 letters or more, the change in central retinal
thickness, the mean change in ETDRS BCVA, the extent of fluorescein leakage, the change in
fundus autofluorescence change in size of neovascular membrane, and the change in central
retinal sensitivity. This is a pilot study designed to evaluate the feasibility and potential
efficacy of treating patients with macular telangiectasia in a larger, phase III study within
the organization of the MAC TEL Research Group, sponsored by the Lowy Foundation. Currently,
the research group is enrolling 200 patients affected with this condition for a natural
history study in 22 international clinical centers.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05152524 -
Distal Ischemic Stroke Treatment With Adjustable Low-profile Stentriever
|
N/A | |
Recruiting |
NCT02486484 -
Ziv-aflibercept in Ocular Disease Requiring Anti-VEGF Injection
|
Phase 2 | |
Completed |
NCT00645697 -
Intravitreal Bevacizumab in Recalcitrant Inflammatory Ocular Neovascularization
|
Phase 4 | |
Recruiting |
NCT04844619 -
KDR2-2 Suspension Eyedrop in the Treatment of Neovascular Glaucoma (KDR-NVG) Trial
|
Phase 1 |